ITEM METADATA RECORD
Title: Significant impact of transient deterioration of renal function on dosimetry in PRRT
Authors: Van Binnebeek, Sofie ×
Baete, Kristof
Terwinghe, C
Vanbilloen, B
Haustermans, Karin
Mortelmans, Luc
Borbath, I
Van Cutsem, Eric
Verslype, Chris
Mottaghy, FM
Verbruggen, A
Deroose, Christophe #
Issue Date: Jan-2013
Publisher: Japanese Society of Nuclear Medicine
Series Title: Annals of Nuclear Medicine vol:27 issue:1 pages:74-77
Abstract: Peptide receptor radionuclide therapy (PRRT), with (90)Y-DOTATOC and (177)Lu-DOTATATE as most clinically used radiopeptides, is widely used in the management of metastatic neuroendocrine tumors. With respect to radiation dosimetry, the kidneys are the critical organ for (90)Y-DOTATOC. Renal irradiation is significant because of reabsorption of the radiopeptide from the proximal tubuli and the resulting retention in the interstitium, mainly in the inner cortical zone. The high energy and consequently wide range in tissue of the yttrium-90 beta particle result in high absorbed doses to the kidney cortex and medulla. Accurate renal dosimetry can help minimizing radiation nephropathy. We report a case of a 69-year-old candidate for PRRT with an acceptable kidney function at the time of screening. When performing (111)In-octreotide pretreatment dosimetry 3 weeks later, we observed a drastic deterioration in kidney function, caused by undisclosed non-steroidal anti-inflammatory drug intake. The calculated kidney biological effective dose (BED) was 153 Gy after four projected cycles. PRRT was canceled as our full-course BED limit is 37 Gy and the patient was switched to morphine analgesics. Renal function normalized after 3 months and repeated dosimetry yielded an acceptable kidney BED of 28 Gy after four projected cycles (7 Gy/cycle). This case emphasizes that acute kidney insufficiency can yield toxic kidney doses in a single therapy cycle, with an inherent risk of persistent renal insufficiency. All clinical factors which might influence kidney function should be verified at screening and before PRRT administration.
ISSN: 0914-7187
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Hepatology
Departement Gezondheidszorg & Technologie - KHLeuven
Clinical Digestive Oncology (+)
Nuclear Medicine & Molecular Imaging
Laboratory of Experimental Radiotherapy
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

 


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science